Tricuspid valve regurgitation: current diagnosis and treatment

Robert J Henning, Robert J Henning

Abstract

Tricuspid regurgitation (TR) is present in 1.6 million individuals in the United States and 3.0 million people in Europe. Functional TR, the most common form of TR, is caused by cardiomyopathies, LV valve disease, or pulmonary disease. The five-year survival with severe TR and HFrEF is 34%. Echocardiography can assess the TR etiology/severity, measure RA and RV size and function, estimate pulmonary pressure, and characterize LV disease. Management includes diuretics, ACE inhibitors, and aldosterone antagonists. Surgical annuloplasty or valve replacement should be considered in patients with progressive RV dilatation without severe LV dysfunction and pulmonary hypertension. Transcatheter repair/replacement is possible in patients with a LVEF <40%, dilated annuli, and impaired RV function. The diagnosis and treatment of TR, including coaptation, annuloplasty devices and prosthetic valves, success rates, morbidity/mortality, and trials are discussed. Transcatheter tricuspid valve repair/replacement is an emerging therapy for high-risk patients with TR who would otherwise have a dismal clinical prognosis.

Keywords: Tricuspid valve anatomy; functional tricuspid regurgitation; primary tricuspid regurgitation; transcatheter tricuspid valve repair; tricuspid valve surgery.

Conflict of interest statement

None.

AJCD Copyright © 2022.

Figures

Figure 1
Figure 1
Normal Tricuspid Valve anatomy.
Figure 2
Figure 2
Transcatheter devices for TV coaptation, annuloplasty, or vena cava valve insertion. Device figures reproduced with permission from the manufacturers.
Figure 3
Figure 3
Transcatheter TV replacement valves: Gate (A), Cardiovalve (B), Evoque (C), Intrepid (D) Valves. Valve figures reproduced with permission of the manufacturers.

References

    1. Kolte D, Elmaria S. Current state of transcatheter tricuspid valve repair. Cardiovasc Diagn Ther. 2020;10:89–97.
    1. Nath J, Foster E, Heidenreich P. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol. 2004;43:405–409.
    1. Badano L, Muraru D, Enriquez-Sarano M. Assessment of functional tricuspid regurgitation. Eur Heart J. 2013;34:1875–1885.
    1. Kwak JJ, Kim YJ, Kim MK, Kim HK, Park JS, Kim KH, Kim KB, Ahn H, Sohn DW, Oh BH, Park YB. Development of tricuspid regurgitation late after left-sided valve surgery: a single-center experience with longterm echocardiographic examinations. Am Heart J. 2008;155:732–737.
    1. Chorin E, Rozenbaum Z, Topilsky Y, Konigstein M, Ziv-Baran T, Richert E, Keren G, Banai S. Tricuspid regurgitation and long-term clinical outcomes. Eur Heart J Cardiovasc Imaging. 2020;21:157–165.
    1. Wang N, Fulcher J, Abeysuriya N, McCrady M, Wilcox I, Celermajer D, Lal S. Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis. Eur Heart J. 2019;40:476–484.
    1. Dahou A, Levin D, Reisman M, Hahn R. Anatomy and physiology of the tricuspid valve. JACC Cardiovasc Imaging. 2019;12:458–468.
    1. Lancellotti P, Moura L, Pierard LA, Agricola E, Popescu BA, Tribouilloy C, Hagendorff A, Monin JL, Badano L, Zamorano J. European association of echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease) Eur J Echocardiogr. 2010;11:307–332.
    1. Buzzati N, De Bonis M, Moat N. Anatomy of the tricuspid valve, pathophysiology of functional tricuspid regurgitation, and implications for percutaneous therapies. Interv Cardiol Clin. 2018;7:1–11.
    1. Yucel E, Bertrand P, Churchill J, Narasivayam M. The tricuspid valve in review: anatomy, pathophysiology and echocardiographic assessment with focus on functional tricuspid regurgitation. J Thorac Dis. 2020;12:2945–2954.
    1. Silver M, Lam J, Ranganathan N, Wigix E. Morphology of the human tricuspid valve. Circulation. 1971;43:333–348.
    1. Lama P, Tamang B, Kulkarni J. Morphometry and aberrant morphology of the adult human tricuspid valve leaflets. Anat Sci Int. 2016;91:143–150.
    1. Dreyfus G, Martin R, Chan K, Dulguerov F, Alexandrescu C. Functional tricuspid regurgitation: a need to revise our understanding. J Am Coll Cardiol. 2015;65:2331–2336.
    1. van Rosendael P, Kamperidis V, Kong W, van Rosendael A, van der Kley F, Marsan N, Delgado V, Bax J. Computed tomography for planning transcatheter tricuspid valve therapy. Eur Heart J. 2018;38:665–674.
    1. Rogers J, Bolling S. The tricuspid valve. Circulation. 2009;119:2718–2725.
    1. Prihad E. Tricuspid valve regurgitation: no longer the “forgotten valve”. European J Cardiol Practice. 2018;16:13.
    1. Silbiger J. Atrial functional tricuspid regurgitation: an underappreciated cause of secondary tricuspid regurgitation. Echocardiography. 2019;36:954–957.
    1. Fender E, Petrescu I, Ionescu F, Zack C, Pislaru S, Nkomo V, Cochuyt J, Hodge D, Nishimura R. Prognostic importance and predictors of survival in isolated tricuspid regurgitation: a growing problem. Mayo Clin Proc. 2019;94:2032–2039.
    1. Axtell A, Bhambhani V, Moonsamy P, Healy E, Picard M, Sundt T, Wasfy J. Surgery does not improve survival in patients with isolated severe tricuspid regurgitation. J Am Coll Cardiol. 2019;74:715–725.
    1. Benfari G, Antoine C, Miller W, Thapa P, Topilsky Y, Rossi A, Michelena H, Pislaru S, Enrique-Saran M. Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction. Circulation. 2019;140:196–206.
    1. Toplisky Y. Indications for surgery for tricuspid regurgitation. Interv Cardiol. 2015;10:58–60.
    1. LaPar DJ, Likosky DS, Zhang M, Theurer P, Fonner CE, Kern JA, Bolling SF, Drake DH, Speir AM, Rich JB, Kron IL, Prager RL, Ailawadi G Investigators for the Virginia Cardiac Surgery Quality Initiative and the Michigan Society of Thoracic and Cardiovascular Surgeons. Development of a risk prediction model and clinical risk score for isolated tricuspid valve surgery. Ann Thorac Surg. 2018;106:129–136.
    1. Lauten A, Alushi B. True registry: a prognostic risk score for risk stratification of patients with severe tricuspid regurgitation (FTR) TCT. 2019
    1. Zoghbi W, Adams D, Bonow R, Enriquez-Sarano M, Foster E, Grayburn P, Hahn R, Han Y, Hung J, Lang R, Little S, Shah D, Shernan S, Thavendiranathan P, Thomas J, Weissman N. Recommendations for noninvasive evaluation of native valvular regurgitation a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular magnetic resonance. J Am Soc Echocardiogr. 2017;30:303–371.
    1. Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, Pierard LA, Badano L, Zamorano JL Scientific Document Committee of the European Association of Cardiovascular Imaging. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2013;14:611–644.
    1. Hahn R, Amorano J. The need for a new tricuspid regurgitation grading scheme. Eur Heart J Cardiovasc Imaging. 2017;18:1342–1343.
    1. Go Y, Dulgheru R, Lancellotti P. The conundrum of tricuspid regurgitation grading. Front Cardiovasc Med. 2018;5:164.
    1. Tadic M, Nita N, Schneider L, Kersten J, Buckert D, Gonska B, Scharnbeck D, Reichart C, Belyavskly E, Cuspidi C, Rottbauer W. The predictive value of right ventricular longitudinal strain in pulmonary hypertension, heart failure, and valvular diseases. Front Cardiovasc Med. 2021;17:698158.
    1. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O’Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A, Toly C. 2020 ACC/AHA guideline for the management of patients with valvular heart disease. Circulation. 2021;143:e35–e71.
    1. Saremi F, Hassani C, Millan-Nunez V, Sánchez-Quintana D. Imaging evaluation of tricuspid valve: analysis of morphology and function with CT and MRI. AJR Am J Roentgenol. 2015;204:W531–42.
    1. Park J, Kim H, Jung J, Klem I, Yoon Y, Lee S, Park E, Hwang H, Lee W, Kim K, Kim Y, Cho G, Kim K, Sohn D, Ahn H. Prognostic value of cardiac MR imaging for preoperative assessment of patients with severe functional tricuspid regurgitation. Radiology. 2018;280:723–734.
    1. Naoum C, Blanke P, Cavalcante J, Leipsic J. Cardiac computed tomography and magnetic resonance imaging in the evaluation of mitral and tricuspid valve disease implications for transcatheter interventions. Circ Cardiovasc Imaging. 2010;10:e50031.
    1. Jacobs K, Rigdon J, Chan F, Cheng JY, Alley M, Vasanawala S, Maskatia S. Direct measurement of atrioventricular valve regurgitant jets using 4D flow cardiovascular magnetic resonance is accurate and reliable for children with congenital heart disease: a retrospective cohort study. J Cardiovasc Magn Reson. 2020;22:33.
    1. Ramsdell G, Nelson J, Pislaru S, Ramakrishna H. Tricuspid regurgitation in congestive heart failure: management strategies and analysis of outcomes. J Cardiothorac Vasc Anesth. 2021;35:1205–1214.
    1. Baumgartner H, Falk V, Bax J, De Bonis M, Hamm C, Holm P, Lung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, Rosenhek R, Sjögren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano J. ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–2791.
    1. Gammie JS, Chu MWA, Falk V, Overbey JR, Moskowitz AJ, Gillinov M, Mack MJ, Voisine P, Krane M, Yerokun B, Bowdish ME, Conradi L, Bolling SF, Miller MA, Taddei-Peters WC, Jeffries NO, Parides MK, Weisel R, Jessup M, Rose EA, Mullen JC, Raymond S, Moquete EG, O’Sullivan K, Marks ME, Iribarne A, Beyersdorf F, Borger MA, Geirsson A, Bagiella E, Hung J, Gelijns AC, O’Gara PT, Ailawadi G CTSN Investigators. Concomitant tricuspid repair in patients with degenerative mitral regurgitation. N Engl J Med. 2021 [Epub ahead of print]
    1. Besler C, Seeburger J, Thiele H, Lurz P. Treatment options for severe functional tricuspid regurgitation: indications, techniques and current challenges. ESC European J Cardiol Practice. 2018:16.
    1. Antunes MJ, Rodríguez-Palomares J, Prendergast B, De Bonis M, Rosenhek R, Al-Attar N, Barili F, Casselman F, Folliguet T, Iung B, Lancellotti P, Muneretto C, Obadia JF, Pierard L, Suwalski P, Zamorano P ESC Working Groups of Cardiovascular Surgery and Valvular Heart Disease. Management of tricuspid valve regurgitation: position statement of the European Society of Cardiology Working Groups of Cardiovascular Surgery and Valvular Heart Disease. Eur J Cardiothorac Surg. 2017;52:1022–1030.
    1. Pagnesi M, Montalto C, Mangieri A, Agricola E, Puri R, Chiarito M, Ancona M, Regazzoli D, Testa L, De Bonis M, Moat N, Rodés-Cabau J, Colombo A, Latib A. Tricuspid annuloplasty versus a conservative approach in patients with functional tricuspid regurgitation undergoing left-sided heart valve surgery: a study-level meta-analysis. Int J Cardiol. 2017;240:138–144.
    1. Hamandi M, Smith R, Ryan W, Grayburn P, Vasudevan A, George T, DiMaio J, Hutcheson K, Brinkman W, Szerlip M, Moore D, Mack M. Outcomes of isolated tricuspid valve surgery have improved in the modern era. Ann Thorac Surg. 2019;108:11–15.
    1. McCarthy P, Bhudia S, Rajeswaran J, Hoercher KJ, Lytle B, Cosgrove D, Blackstone E. Tricuspid valve repair: durability and risk factors for failure. J Thorac Cardiovasc Surg. 2004;127:674–685.
    1. Lu S, Song K, Yao W, Xia L, Dong L, Sun Y, Hong T, Yang S, Wang C. Simplified, minimally invasive, beating-heart technique for redo isolated tricuspid valve surgery. J Cardiothorac Surg. 2020;15:146.
    1. Taramasso M, Gavazzoni M, Pozzoli A, Dreyfus GD, Bolling SF, George I, Kapos I, Tanner FC, Zuber M, Maisano F, Hahn RT. Tricuspid regurgitation predicting the need for intervention, procedural success, and recurrence of disease. JACC Cardiovasc Imaging. 2019;12:605–621.
    1. Nosair A, Elkahely M, Nasr S, Alkady H. Tricuspid three-dimensional ring versus fashioned flexible band annuloplasty in management of functional tricuspid valve regurge: comparative long term study. The Cardiothoracic Surgeon. 2020;28:13.
    1. Shinn S, Schaff H. Evidence-based surgical management of acquired tricuspid valve disease. Nat Rev Cardiol. 2013;10:190–203.
    1. Guenther T, Noebauer C, Mazzitelli D, Busch R, Tassani-Prell P, Lange R. Tricuspid valve surgery: a thirty-year assessment of early and late outcome. Eur J Cardiothorac Surg. 2008;34:402–409.
    1. Fukunaga N, Koyama T. Early and late outcomes of isolated tricuspid valve surgery following valvular surgery. Ann Thorac Cardiovasc Surg. 2019;25:111–116.
    1. Buzzatti N, Laci G, Taramasso M, Nisi T, Lapenna E, De Bonis M, Maisano F, Alfieri O. Long-term outcomes of tricuspid valve replacement after previous leftside heart surgery. Eur J Cardiothorac Surg. 2014;46:713–719.
    1. Alqahtani F, Berzingi CO, Aljohani S, Hijazi M, Al-Hallak A, Alkhouli M. Contemporary trends in the use and outcomes of surgical treatment of tricuspid regurgitation. J Am Heart Assoc. 2017;6:e007597.
    1. Moraca RJ, Moon MR, Lawton JS, Guthrie TJ, Aubuchon KA, Moazami N, Pasque MK, Damiano RJ Jr. Outcomes of tricuspid valve repair and replacement: a propensity analysis. Ann Thorac Surg. 2009;87:83–88.
    1. Nickenig G, Kowalski M, Hausleiter J, Braun D, Schofer J, Yzeiraj E, Rudolph V, Friedrichs K, Maisano F, Taramasso M, Fam N, Bianchi G, Bedogni F, Denti P, Alfieri O, Latib A, Colombo A, Hammerstingl C, Schueler R. Transcatheter treatment of severe tricuspid regurgitation with the edge-to-edge MitraClip technique. Circulation. 2017;135:1802–1814.
    1. Taramasso M, Hahn R, Alessandrini H, Latib A, Attinger-Toller A, Braun D, Brochet E, Connelly K, Denti P, Deuschl F, Englmaier A, Fam N, Frerker C, Hausleiter J, Juliard J, Kaple R, Kreidel F, Kuck K, Kuwata S, Ancona M, Malasa M, Nazif T, Nickenig G, Nietlispach F, Pozzoli A, Schäfer U, Schofer J, Schueler R, Tang G, Vahanian A, Webb JG, Yzeiraj E, Maisano F, Leon M. The international multicenter TriValve registry: which patients are undergoing transcatheter tricuspid repair? JACC Cardiovasc Interv. 2017;10:1982–1990.
    1. Hammerstingl C, Schueler R, Malasa M, Werner N, Nickenig G. Transcatheter treatment of severe tricuspid regurgitation with the MitraClip system. Eur Heart J. 2016;37:849–853.
    1. Besler C, Orban M, Rommel KP, Braun D, Patel M, Hagl C, Borger M, Nabauer M, Massberg S, Thiele H, Hausleiter J, Lurz P. Predictors of procedural and clinical outcomes in patients with symptomatic tricuspid regurgitation undergoing transcatheter edge-to-edge repair. JACC Cardiovasc Interv. 2008;11:1119–1128.
    1. Giannini F, Colombo A. Percutaneous treatment of tricuspid valve in refractory right heart failure. Eur Heart J Suppl. 2019;21(Suppl B):B43–B47.
    1. Santalo-Corcoy M, Asmarats L, Li CH, Arzamendi D. Catheter-based treatment of tricuspid regurgitation: state of the art. Ann Transl Med. 2020;8:964.
    1. Orban M, Rommel K, Ho E, Unterhuber M, Pozzoli A, Connelly K, Deseive S, Besler C, Ong G, Braun D, Edwards J, Miura M, Gülmez G, Stolz L, Gavazzoni M, Zuber M, Orban M, Nabauer M, Maisano F, Thiele H, Massberg S, Taramasso M, Fam NP, Lurz P, Hausleiter J. Transcatheter edge-to-edge tricuspid repair for severe tricuspid regurgitation reduces hospitalizations for heart failure. JACC Heart Fail. 2020;8:265–276.
    1. Ruf TF, Hahn RT, Kreidel F, Beiras-Fernandez A, Hell M, Gerdes P, da Roche E Silva JG, Vosseler M, Geyer M, Tamm A, Münzel T, von Bardeleben RS. Short-term clinical outcomes of transcatheter tricuspid valve repair with the third-generation MitraClip XTR system. JACC Cardiovasc Interv. 2021;14:1231–1240.
    1. Lurz P, Stephan von Bardeleben R, Weber M, Sitges M, Sorajja P, Hausleiter J, Denti P, Trochu J, Nabauer M, Tang G, Biaggi P, Ying S, Trusty P, Dahou A, Hahn R, Nickenig G TRILUMINATE Investigators. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol. 2021;77:229–239.
    1. Kitamura M, Fam N, Braun D, Ruf T, Sugiura A, Narang A, Connelly KA, Ho E, Nabauer M, Hausleiter J, Weber M, Nickenig G, Davidson CJ, Thiele H, von Bardeleben RS, Lurz P. 12-month outcomes of transcatheter tricuspid valve repair with the PASCAL system for severe tricuspid regurgitation. Catheter Cardiovasc Interv. 2021;97:1281–1289.
    1. Braun D, Löw K, Orban M, Mehr M, Gmeiner J, Massberg S, Nabauer M, Hausleiter J. Mitraclip XTR VS. pascal transcatheter valve repair system for edge-to edge repair of severe tricuspid regurgitation. J Am Coll Cardiol. 2020;75(Suppl 1):1135.
    1. Kodali S, Hahn R, Eleid M, Kipperman R, Smith R, Lim D, Gray W, Narang A, Pislaru S, Koulogiannis K, Grayburn P, Fowler D, Hawthorne K, Dahou A, Deo S, Vandrangi P, Deuschl F, Mack M, Leon M, Feldman T, Davidson C CLASP TR EFS Investigators. Feasibility study of the transcatheter valve repair system for severe tricuspid regurgitation. J Am Coll Cardiol. 2021;77:345–356.
    1. NCT02787408. The SPACER trial - repair of tricuspid valve regurgitation using the Edwards tricuspid transcatheter repair system (SPACER) .
    1. Perlman G, Praz F, Puri R, Ofek H, Ye J, Philippon F, Carrel T, Pibarot P, Attinger A, Htun N, Dvir D, Moss R, Campelo-Parada F, Bédard E, Reineke D, Moschovitis A, Lauck S, Blanke P, Leipsic J, Windecker S, Rodés-Cabau J, Webb J. Transcatheter tricuspid valve repair with a new transcatheter coaptation system for the treatment of severe tricuspid regurgitation: 1-year clinical and echocardiographic results. JACC Cardiovasc Interv. 2017;10:1994–2003.
    1. Asmarats L, Perlman G, Praz F, Hensey M, Chrissoheris M, Philippon F, Ofek H, Ye J, Puri R, Pibarot P, Attinger A, Moss R, Bédard E, Moschovitis A, Reineke D, Lauck S, Blanke P, Leipsic J, Spargias K, Windecker S, Webb JG, Rodés-Cabau J. Long-term outcomes of the forma transcatheter tricuspid valve repair system for the treatment of severe tricuspid regurgitation: insights from the first-in-human experience. JACC Cardiovasc Interv. 2019;12:1438–1447.
    1. Asmarats L, Philippon F, Bédard E, Rodés-Cabau J. Forma tricuspid repair system: device enhancements and initial experience. EuroIntervention. 2019;14:1656–1657.
    1. Hahn RT, Meduri CU, Davidson CJ, Lim S, Nazif TM, Ricciardi MJ, Rajagopal V, Ailawadi G, Vannan MA, Thomas JD, Fowler D, Rich S, Martin R, Ong G, Groothuis A, Kodali S. Early feasibility study of a transcatheter tricuspid valve annuloplasty: SCOUT trial 30-day results. J Am Coll Cardiol. 2017;69:1795–1806.
    1. NCT03225612. Safety and performance of the trialign percutaneous tricuspid valve annuloplasty system (SCOUT-II) .
    1. NCT03779490. Transcatheter repair of tricuspid regurgitation with cardioband TR system post market study (TriBAND): a European prospective, multicenter post-market clinical follow-up study to assess transcatheter tricuspid valve repair with edwards cardioband TR system in patients with symptomatic, chronic functional tricuspid regurgitation. .
    1. von Bardekeben R, Kreidel F. One-year outcomes of the TRI-REPAIR study assessing cardioband tricuspid valve reconstruction system for patients with functional tricuspid regurgitation. J Card Fail. 2019;25:S11.
    1. Davidson C, Lim D, Smith R, Kodali S, Kipperman R, Eleid M, Reisman M, Whisenant B, Puthumana J, Abramson S, Fowler D, Grayburn P, Hahn R, Koulogiannis K, Pislaru S, Zwink T, Minder M, Dahou A, Deo S, Vandrangi P, Deuschl F, Feldman T, Gray W Cardioband TR EFS Investigators. Early feasibility study of cardioband tricuspid system for functional tricuspid regurgitation: 30-day outcomes. JACC Cardiovasc Interv. 2021;14:1–50.
    1. Nickenig G On Behalf of The TRILUMINATE Investigators. Percutaneous edge-to-edge repair for tricuspid regurgitation: initial 1-year outcomes from the TRILUMINATE clinical trial. PCR London Valves. 2019
    1. Tang G. Tricuspid Clip in Tricuspid Regurgitation. . Feb 21, 2020.
    1. Eleid M. Six month results of the CLASP TR trial. EuroPCR. 2021
    1. Asmarats L, Philippon F, Bédard E, Rodés-Cabau J. FORMA tricuspid repair system: device enhancements and initial experience. EuroIntervention. 2019;14:1656–1657.
    1. Perlman GY, Dvir D. Treatment of tricuspid regurgitation with the FORMA repair system. Front Cardiovasc Med. 2018;5:140.
    1. Nickenig G, Weber M, Schüler R, Hausleiter J, Nabauer M, von Bardeleben RS, Sotiriou E, Schäfer U, Deuschl F, Alessandrini H, Kreidel F, Juliard JM, Brochet E, Latib A, Montorfano M, Agricola E, Baldus S, Friedrichs KP, Deo SH, Gilmore SY, Feldman T, Hahn RT, Maisano F. Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study. EuroIntervention. 2021;16:e1264–e1271.
    1. Nickening G. Initial results of the Triband study. EuroPCR. 2021
    1. Nickenig G, Friedrichs KP, Baldus S, Arnold M, Seidler T, Hakmi S, Linke A, Schäfer U, Dreger H, Reinthaler M, von Bardeleben RS, Möllmann H, Weber M, Roder F, Körber MI, Landendinger M, Wolf F, Alessandrini H, Sveric K, Schewel D, Romero-Dorta E, Kasner M, Dahou A, Hahn RT, Windecker S. Thirty-day outcomes of the cardioband tricuspid system for patients with symptomatic functional tricuspid regurgitation: the TriBAND study. EuroIntervention. 2021;17:809–817.
    1. Hahn R. State-of-the-art review of echocardiographic imaging in the evaluation and treatment of functional tricuspid regurgitation. Circ Cardiovasc Imaging. 2016;9:e005332.
    1. Goldberg Y, Ho E, Chau M, Latib A. Update on transcatheter tricuspid valve replacement therapies. Front Cardiovasc Med. 2021;8:19558.
    1. Dreger H, Mattig I, Hewing B, Knebel F, Lauten A, Lembcke A, Thoenes M, Roehle R, Stangl V, Landmesser U, Grubitzsch H, Stangl K, Laule M. Treatment of severe TRIcuspid regurgitation in patients with advanced heart failure with CAval vein implantation of the Edwards Sapien XT valve (TRICAVAL): a randomised controlled trial. EuroIntervention. 2020;15:1506–1513.
    1. NCT02339974. Heterotopic implantation of the Edwards-sapien transcatheter aortic valve in the inferior VEna cava for the treatment of severe tricuspid regurgitation (HOVER) .
    1. NCT04141137. TRICUS STUDY Euro - safety and efficacy of the TricValve® device. .
    1. Hahn R. NAVIGATE transcatheter tricuspid valve replacement: early findings; technology and clinical updates. Session 3: TranscatheterTranscatheter Therapies for TR - Promise and Pitfalls Sunday, September 23, 2018
    1. Aoi S, Wiley J, Ho E, Goldberg Y, Chau M, Latib A. Transcatheter tricuspid valve implantation with the cardiovalve system. Future Cardiol. 2021;17:963–969.
    1. NCT04100720. Early feasibility study of the cardiovalve system for tricuspid regurgitation. .
    1. Kodali S. Initial results of the triscend trial. Presented at EuroPCR. 2021
    1. NCT04482062. TRISCEND II pivotal trial. .
    1. Bapat V. The INTREPID valve for severe tricuspid regurgitation: case experience. In: CRT 2020 (2020)

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться